Events and Presentations

UPCOMING EVENTS AND PRESENTATIONS

There are currently no events to display.

ARCHIVED EVENTS AND PRESENTATIONS

Date Event Details Remind Me
Summary Toggle 09/11/13
10:50 AM EDT
Summary Toggle 02/26/15
8:00 AM EST
Summary Toggle 11/9/10
5:00 PM EST
Summary Toggle 07/24/12
8:00 AM EDT
Click here to view slides if you are dialing into the conference call.
Summary Toggle 08/13/13
8:35 AM EDT
Summary Toggle 01/15/15
12:00 PM PST
Chris Garabedian, Sarepta's president and chief executive officer, will be the presenter.

Supporting Materials

Summary Toggle 09/20/10
10:30 AM EDT
Summary Toggle 04/25/12
12:00 PM EDT

Presented today at the American Academy of Neurology 64th Annual Meeting in New Orleans, Louisiana. Principal investigator, Jerry R. Mendell, M.D. of Nationwide Children's Hospital. A brief oral presentation of the abstract titled "A Phase IIb Placebo-Controlled Study of the Exon-Skipping Drug Eteplirsen in Subjects with Duchenne Muscular Dystrophy" during the AAN Emerging Science Session at 5:54 pm CDT, followed by a more detailed poster presentation (6:30 to 7:00 pm CDT).

Summary Toggle 07/10/13
11:00 AM EDT
Summary Toggle 12/10/14
11:30 AM EST

This section of our website may contain dated or archived information which should not be considered current and may no longer be accurate. For current information, you are encouraged to review our most recent official corporate documents on file with the U.S. Securities and Exchange Commission.
Sarepta's recorded events and presentations contain forward-looking statements that involve risks and uncertainties, including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the company's Securities and Exchange Commission filings. Sarepta undertakes no obligation to revise or update the progress of these milestones except to the extent required under applicable federal and state securities laws.